Leap Therapeutics (NASDAQ:LPTX) Cut to “Neutral” at Robert W. Baird

by · The Markets Daily

Robert W. Baird cut shares of Leap Therapeutics (NASDAQ:LPTX – Free Report) from an outperform rating to a neutral rating in a report released on Wednesday morning, MarketBeat reports. The firm currently has $1.25 price target on the stock, down from their prior price target of $9.00.

Separately, HC Wainwright reissued a “buy” rating and issued a $5.50 target price on shares of Leap Therapeutics in a research note on Thursday, January 16th.

Get Our Latest Analysis on Leap Therapeutics

Leap Therapeutics Stock Performance

LPTX opened at $0.56 on Wednesday. The business’s 50-day simple moving average is $2.74 and its 200 day simple moving average is $2.73. Leap Therapeutics has a 52-week low of $0.51 and a 52-week high of $4.79. The firm has a market capitalization of $21.46 million, a PE ratio of -0.29 and a beta of 0.17.

Hedge Funds Weigh In On Leap Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the company. Simplify Asset Management Inc. grew its holdings in Leap Therapeutics by 67.4% in the 3rd quarter. Simplify Asset Management Inc. now owns 1,056,895 shares of the company’s stock valued at $2,716,000 after buying an additional 425,626 shares in the last quarter. Exome Asset Management LLC acquired a new position in shares of Leap Therapeutics in the third quarter valued at about $264,000. Marshall Wace LLP raised its stake in Leap Therapeutics by 268.2% in the 2nd quarter. Marshall Wace LLP now owns 79,758 shares of the company’s stock worth $156,000 after purchasing an additional 58,094 shares in the last quarter. Geode Capital Management LLC raised its stake in Leap Therapeutics by 18.0% in the 3rd quarter. Geode Capital Management LLC now owns 329,291 shares of the company’s stock worth $847,000 after purchasing an additional 50,194 shares in the last quarter. Finally, Key Client Fiduciary Advisors LLC boosted its holdings in Leap Therapeutics by 12.2% in the 4th quarter. Key Client Fiduciary Advisors LLC now owns 361,253 shares of the company’s stock valued at $1,039,000 after purchasing an additional 39,330 shares during the period. Institutional investors and hedge funds own 30.46% of the company’s stock.

About Leap Therapeutics

(Get Free Report)

Leap Therapeutics, Inc, a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501.

Read More